Stocks · Healthcare · Drug Manufacturers - Specialty & Generic
Supernus Pharmaceuticals, Inc. SUPN
$42.38 +0.47% Close, Oct 2, 2026 · NASDAQ · Market cap $2.46B
Low risk
Next earnings report: Nov 3, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $-1.92, down 267.1% year over year.
- Operating margin narrowed to -13.5% from 9.6% a year earlier.
- Earnings beat analyst estimates in each of the last 8 quarters (average surprise over the last four: +97.6%).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 28%
- EPS growth (TTM, YoY)Bottom 8%
- FCF growth (TTM, YoY)Bottom 14%
- Revenue growth, 3-year CAGRBottom 30%
- Revenue growth accelerationTop 14%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 42%
- Gross marginTop 21%
- Operating marginBottom 45%
- Accruals (lower is better)Top 38%
- Interest coverBottom 17%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 42%
- Free-cash-flow yieldTop 33%
- EBITDA / enterprise valueTop 39%
- Sales / enterprise valueTop 36%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 31%
- 6-month returnBottom 27%
- 1-year return vs S&P 500Bottom 35%
- Distance from 52-week highTop 45%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 8%
- Consecutive EPS beatsTop 8%
- Share of analysts rating BuyBottom 30%
- Upside to consensus price targetBottom 38%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 15%
- Maximum drawdown, 3 yearsTop 4%
- Beta vs S&P 500 (lower is better)Top 25%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 16.3% | 24.9% | ↑ |
| EPS growth (YoY) | -146.1% | -267.1% | ↓ |
| Gross margin | 88.5% | 88.1% | ↓ |
| Operating margin | 9.6% | -13.5% | ↓ |
| FCF margin | 27.9% | 2.3% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 24.9% | 16.3% | ↑ | Top 28% |
| EPS growth (TTM, YoY) | -267.1% | -146.1% | ↓ | Bottom 8% |
| Gross margin | 88.1% | 88.5% | ↓ | Top 21% |
| Operating margin | -13.5% | 9.6% | ↓ | Bottom 45% |
| Net margin | -13.2% | 9.7% | ↓ | — |
| Free-cash-flow margin | 2.3% | 27.9% | ↓ | — |
| Return on invested capital | -9.1% | — | Top 42% | |
| Revenue growth, 3-year CAGR | 2.5% | — | Bottom 30% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -9.1%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 7.0%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +25.4 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -48.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -2.04%
- Shareholder yield
- -2.04%
- Share count change, 1 year
- +2.5%
- Share count change, 3-year CAGR
- +2.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 3, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 8
- Beats in the last 8 reports
- 8 of 8
- Average EPS surprise, last 4
- +97.6%
- Average 2-day reaction, last 8
- +2.0%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $57.60
- Target vs current price
- +35.9%
- Analysts with a rating
- 14
- Share rating Buy or Strong Buy
- 64%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 3, 2026 | +27.8% | +3.1% | +6.7% | -2.0% | — |
| May 5, 2026 | +110.7% | +1.2% | +1.5% | -9.4% | -6.2% |
| Feb 24, 2026 | +228.6% | +5.1% | +8.7% | -2.8% | -6.1% |
| Nov 4, 2025 | +23.2% | +2.3% | -18.5% | -20.8% | -13.5% |
| Aug 5, 2025 | +93.6% | +1.3% | +9.5% | +20.2% | +43.5% |
| May 6, 2025 | +10.5% | +0.1% | -0.7% | -0.5% | +8.4% |
| Feb 25, 2025 | +63.0% | +0.4% | -2.9% | +0.1% | +1.6% |
| Nov 4, 2024 | +171.8% | +2.1% | +7.7% | +9.8% | +13.0% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 3, 2026 | $0.54 | $0.42 | +27.8% | $219.1M |
| May 5, 2026 | $0.59 | $0.28 | +110.7% | $207.7M |
| Feb 24, 2026 | $0.92 | $0.28 | +228.6% | $211.6M |
| Nov 4, 2025 | $1.01 | $0.82 | +23.2% | $192.1M |
| Aug 5, 2025 | $0.91 | $0.47 | +93.6% | $165.5M |
| May 6, 2025 | $0.42 | $0.38 | +10.5% | $149.8M |
| Feb 25, 2025 | $0.75 | $0.46 | +63.0% | $174.2M |
| Nov 4, 2024 | $1.06 | $0.39 | +171.8% | $175.7M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (forward) | 16.5× | — | — | — |
| EV / Sales | 2.79× | — | — | Top 36% |
| Free-cash-flow yield | 0.76% | — | — | Top 33% |
| Earnings yield | -4.53% | — | — | Top 42% |
P/E over the past five years
Range 14.3× – 298.8× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- -11.8%
- Earnings per share growth (TTM)
- -267.1%
- Change in P/E multiple
- -89.1%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -4.2%
- 200-day average slope (20 days)
- -0.6%
- Distance from 50-day average
- -5.2%
- Distance from 200-day average
- -12.1%
- RSI (14)
- 43.9
- Relative volume
- 1.17×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 34.2%
- Volatility vs own 5-year history
- 48th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.66
- Correlation with S&P 500
- 0.31
- Current drawdown from 1-year high
- -25.6%
- Maximum drawdown, 3 years
- -27.6%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 2, 2023 | Oct 26, 2023 | -45.9% | 184 days | 444 days (Aug 6, 2025) |
| Jun 16, 2021 | Aug 19, 2021 | -29.1% | 45 days | 56 days (Nov 8, 2021) |
| Nov 4, 2025 | Sep 15, 2026 | -27.6% | 215 days | Not yet recovered |
| Apr 7, 2022 | May 11, 2022 | -26.0% | 23 days | 69 days (Aug 19, 2022) |
| Feb 10, 2021 | Mar 4, 2021 | -23.2% | 15 days | 28 days (Apr 14, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $2.46B
- EPS, diluted (TTM)
- -$1.92
- Revenue (TTM)
- $830.4M
- 52-week range
- $40.51 – $59.68
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $579.8M | $667.2M | $607.5M | $661.8M | $719.0M |
| Gross profit | $504.7M | $580.0M | $523.7M | $583.9M | $644.4M |
| Operating income | $86.0M | $46.1M | -$5.3M | $81.7M | -$36.9M |
| Net income | $53.4M | $60.7M | $1.3M | $73.9M | -$38.5M |
| EPS (diluted) | $0.98 | $1.04 | $0.02 | $1.32 | -$0.68 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $175.7M | $174.2M | $149.8M | $165.5M | $192.1M | $211.6M | $207.7M | $219.1M |
| Net income | $38.5M | $15.3M | -$11.8M | $22.5M | -$45.1M | -$4.1M | -$2.3M | -$58.4M |
| EPS (diluted) | $0.69 | $0.27 | -$0.21 | $0.40 | -$0.80 | -$0.07 | -$0.04 | -$1.01 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $127.1M | $116.8M | $111.1M | $172.0M | $47.3M |
| Capital expenditure | -$2.0M | -$412,000 | -$551,000 | -$725,000 | -$1.3M |
| Free cash flow | $125.1M | $116.4M | $110.5M | $171.2M | $46.0M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $7.1M | $12.4M | $6.6M | $14.9M | $37.6M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $372.1M
- Total assets
- $1.43B
- Total liabilities
- $396.9M
- Total debt
- $40.2M
- Net debt
- -$139.8M
- Shareholders’ equity
- $1.03B
As of Jun 30, 2026 (filed Aug 3, 2026).
Short interest
- Shares sold short
- 4,989,421
- Days to cover
- 8.65
- Change vs previous report
- +6.8%
FINRA short interest, settlement date Sep 15, 2026.